Evonik Evonik

X

Find Arfolitixorin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Arfolitixorin
Also known as: Arfolitixorin, 31690-11-6, Modufolin, 6r-mthf, Methylenetetrahydrofolic acid, l-(+)-, Arfolitixorin [usan]
Molecular Formula
C20H23N7O6
Molecular Weight
457.4  g/mol
InChI Key
QYNUQALWYRSVHF-OLZOCXBDSA-N
FDA UNII
Z8R4A37V9Q

Arfolitixorin is the R-isomer of folitixorin, a reduced folate-based biomodulator and active metabolite of folate drugs leucovorin (LV) and levoleucovorin (l-LV) that can be used to increase the efficacy of certain antimetabolites, such as the cytotoxic agent 5-fluorouracil (5-FU), and reduce as well as protect against certain antimetabolite-associated adverse effects, such as those seen with high-dose (HD) methotrexate. Upon administration of arfolitixorin, 5,10-methylenetetrahydrofolate (MTHF) is a reduced folate substrate for the enzyme thymidylate synthase (TS) and stabilizes, upon co-administration of 5-FU, the covalent binding of the 5-FU metabolite 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), instead of deoxyuridine monophosphate (dUMP), to its target enzyme TS, which results in an inhibition of TS. This inhibits the synthesis of deoxythymidine monophosphate (dTMP) and leads to the depletion of thymidine triphosphate (TTP), which is a necessary constituent of DNA. This inhibits DNA synthesis, which leads to an inhibition of cellular proliferation and induces tumor cell death. As MTHF is able to stabilize and strengthen the ternary complex, co-administration of arfolitixorin enhances the inhibition of DNA synthesis and increases the cytotoxic effect of 5-FU. As MTHF is the active form of folate and the active metabolite of LV and l-LV, arfolitixorin does not need to be converted to an active metabolite to become activated. In DNA synthesis, a ternary complex is formed between the reduced folate substrate MTHF, the TS enzyme and dUMP in order to convert dUMP to the DNA building block dTMP, which is necessary for DNA synthesis.
1 2D Structure

Arfolitixorin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-2-[[4-[(6aR)-3-amino-1-oxo-2,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl]benzoyl]amino]pentanedioic acid
2.1.2 InChI
InChI=1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12-,13+/m1/s1
2.1.3 InChI Key
QYNUQALWYRSVHF-OLZOCXBDSA-N
2.1.4 Canonical SMILES
C1C2CN(CN2C3=C(N1)N=C(NC3=O)N)C4=CC=C(C=C4)C(=O)NC(CCC(=O)O)C(=O)O
2.1.5 Isomeric SMILES
C1[C@@H]2CN(CN2C3=C(N1)N=C(NC3=O)N)C4=CC=C(C=C4)C(=O)N[C@@H](CCC(=O)O)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
Z8R4A37V9Q
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 5,10-methylene-5,6,7,8-tetrahydrofolate

2. 5,10-methylenetetrahydrofolate

3. 5,10-methylenetetrahydrofolate Monohydrochloride, (l-glu)-isomer

4. 5,10-methylenetetrahydrofolate, (d-glu)-isomer

5. 5,10-methylenetetrahydrofolate, (l-glu)-(s)-isomer

6. 5,10-methylenetetrahydrofolic Acid

7. Ch2h4fol

8. Ch2h4folate

9. N5,n10-methylene-5,6,7,8-tetrahydrofolic Acid

10. Tetrahydromethylenefolate

2.3.2 Depositor-Supplied Synonyms

1. Arfolitixorin

2. 31690-11-6

3. Modufolin

4. 6r-mthf

5. Methylenetetrahydrofolic Acid, L-(+)-

6. Arfolitixorin [usan]

7. (6r)-5,10-methylenetetrahydrofolic Acid

8. Chebi:1989

9. Z8r4a37v9q

10. Iso-901

11. L-(+)-methylenetetrahydrofolic Acid

12. 5,10-methylene-thf

13. 5,10-methylene-(6r)-tetrahydrofolic Acid

14. (2s)-2-[[4-[(6ar)-3-amino-1-oxo-4,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl]benzoyl]amino]pentanedioic Acid

15. 3432-99-3

16. 5,10-methylenetetrahydrofolate

17. N-({4-[(6ar)-3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9h)-yl]phenyl}carbonyl)-l-glutamic Acid

18. N-{4-[(6ar)-3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9h)-yl]benzoyl}-l-glutamic Acid

19. Unii-z8r4a37v9q

20. Arfolitixorin [inn]

21. Arfolitixorin (usan/inn)

22. Schembl186747

23. Arfolitixorin [who-dd]

24. Chembl1234270

25. Dtxsid60185584

26. Bcp09003

27. Zinc4228243

28. (6r)-5,10-mthf

29. Who 10689

30. Db12676

31. 5,10-methylene,5,6,7,8-tetrahydrofolate

32. D11447

33. D-n5,n10-methylene-l-tetrahydrofolic Acid

34. Q26995704

35. (6r,s)-5,10-methylene-5,6,7,8-tetrahydrofolic Acid

36. [6r]-5,10-methylenetetrahydrofolate ([6r]-5,10- Mthf)

37. (6r)-5,10-methylene-5,6,7,8-tetrahydrofolic Acid

38. (2s)-2-[[4-[(6ar)-3-amino-1-oxo-2,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl]benzoyl]amino]pentanedioic Acid

39. (s)-2-(4-((r)-3-amino-1-oxo-5,6,6a,7-tetrahydroimidazo[1,5-f]pteridin-8(1h,4h,9h)-yl)benzamido)pentanedioic Acid

40. (s)-2-(4-((r)-3-amino-1-oxo-5,6,6a,7-tetrahydroimidazo[1,5-f]pteridin-8(1h,4h,9h)-yl)benzamido)pentanedioicacid

41. L-glutamic Acid, N-(4-((6ar)-3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9h)-yl)benzoyl)-

42. N-({4-[(6ar)-3-amino-1-oxo-1,4,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9h)-yl]phenyl}carbonyl)-l-glutamic Acid

43. N-(4-((6ar)-3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo(1,5-f)pteridin-8(9h)- Yl)benzoyl)-l-glutamic Acid

2.4 Create Date
2019-01-15
3 Chemical and Physical Properties
Molecular Weight 457.4 g/mol
Molecular Formula C20H23N7O6
XLogP3-0.5
Hydrogen Bond Donor Count6
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Exact Mass457.17098148 g/mol
Monoisotopic Mass457.17098148 g/mol
Topological Polar Surface Area190 Ų
Heavy Atom Count33
Formal Charge0
Complexity911
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of colorectal cancer


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY